Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer.
Speetjens FM, Lauwen MM, Franken KL, Janssen-van Rhijn CM, van Duikeren S, Bres SA, van de Velde CJ, Melief CJ, Kuppen PJ, van der Burg SH, Morreau H, Offringa R. Speetjens FM, et al. Among authors: van duikeren s, van der burg sh, van de velde cj. Int J Cancer. 2008 Aug 15;123(4):838-45. doi: 10.1002/ijc.23570. Int J Cancer. 2008. PMID: 18506693 Free article.
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH. Speetjens FM, et al. Among authors: van der burg sh, van de velde cj. Clin Cancer Res. 2009 Feb 1;15(3):1086-95. doi: 10.1158/1078-0432.CCR-08-2227. Clin Cancer Res. 2009. PMID: 19188184 Free article. Clinical Trial.
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S. Verdegaal EM, et al. Among authors: van steijn ja, van der burg sh, van der minne ce. Cancer Immunol Immunother. 2011 Jul;60(7):953-63. doi: 10.1007/s00262-011-1004-8. Epub 2011 Mar 24. Cancer Immunol Immunother. 2011. PMID: 21431917 Free PMC article. Clinical Trial.
Colorectal cancer vaccines in clinical trials.
Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Speetjens FM, et al. Among authors: van der burg sh. Expert Rev Vaccines. 2011 Jun;10(6):899-921. doi: 10.1586/erv.11.63. Expert Rev Vaccines. 2011. PMID: 21692708 Review.
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, Oostendorp J, Fathers LM, Drijfhout JW, van de Velde CJ, Kuppen PJ, van der Burg SH, Melief CJ. Zeestraten EC, et al. Among authors: van der burg sh, van de velde cj. Int J Cancer. 2013 Apr 1;132(7):1581-91. doi: 10.1002/ijc.27819. Epub 2012 Nov 21. Int J Cancer. 2013. PMID: 22948952 Free article. Clinical Trial.
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN. Kvistborg P, et al. Sci Transl Med. 2014 Sep 17;6(254):254ra128. doi: 10.1126/scitranslmed.3008918. Sci Transl Med. 2014. PMID: 25232180
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH. Verdegaal EM, et al. Among authors: van der burg sh, van der minne ce, van buuren mm. Nature. 2016 Aug 4;536(7614):91-5. doi: 10.1038/nature18945. Epub 2016 Jun 27. Nature. 2016. PMID: 27350335
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.
Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM. Melief SM, et al. Among authors: van den berg jh, van der burg sh, van diepen m. Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073773
344 results